Fosun Pharma’s 2010 Interim Release, Near 30% Growth Of Net Profits Of Key Pharmaceutical Enterprises
On Aug. 26, Fosun Pharma reported 2010 interim, indicating Fosun Pharma has achieved main business revenue RMB 2,169,002,700.00, increased 23.71% YoY during the reporting period; achieved net profits attributable to parent company RMB 551,000,000.00 and increased 60.75% YoY; achieved Earnings Per Share (EPS) RMB 0.44 in the first half of fiscal year 2010 and increased 57.14% YoY. It is said the rapid growth of company achievements within the reporting period was mainly benefited from the business increasing of controlled subsidiaries in the segments of the pharmaceutical manufacturing and R&D as well as pharmaceutical commerce, and the business increasing of Sinopharm.
Within the reporting period, the sales revenue and net profits of the key pharmaceutical enterprises such as Chongqing Yao Pharma, Shine Star (Hubei ), and Wangbang Pharma kept rapid growing with the mean growth rate of sales income and net profits of 30% approx.. The report shows that Fosun Pharma has further increased the investment in R&D within the reporting period with the accumulated amount reaching RMB 186 million in the first half of fiscal year 2010.
It is reported that, the pharmaceutical distribution and retailing business of the Fosun Pharma has been maintaining good growth in the first half of fiscal 2010. Sinopharm (1099.HK), the associate company of Fosun Pharm has continuously accelerated industrial integration, maintained rapid growing of business and strengthened the leading position in the pharmaceutical distribution industry. The pharmaceutical retailing brands under Fosun Pharma such as For Me Drug Store and Golden Elephant Drug Store have also continuously kept their leading position of brand and profitability in the regional markets respectively.
In addition, Fosun Pharma has invested Chindex International, Inc. and Biosino Bio-Technology & Science Inc. etc., and it is expected that the business scale and profitability of Fosun Pharma in the fields like healthcare service, medical instruments and medical diagnostics will be further upgraded and enhanced.
Within the reporting period, the sales revenue and net profits of the key pharmaceutical enterprises such as Chongqing Yao Pharma, Shine Star (Hubei ), and Wangbang Pharma kept rapid growing with the mean growth rate of sales income and net profits of 30% approx.. The report shows that Fosun Pharma has further increased the investment in R&D within the reporting period with the accumulated amount reaching RMB 186 million in the first half of fiscal year 2010.
It is reported that, the pharmaceutical distribution and retailing business of the Fosun Pharma has been maintaining good growth in the first half of fiscal 2010. Sinopharm (1099.HK), the associate company of Fosun Pharm has continuously accelerated industrial integration, maintained rapid growing of business and strengthened the leading position in the pharmaceutical distribution industry. The pharmaceutical retailing brands under Fosun Pharma such as For Me Drug Store and Golden Elephant Drug Store have also continuously kept their leading position of brand and profitability in the regional markets respectively.
In addition, Fosun Pharma has invested Chindex International, Inc. and Biosino Bio-Technology & Science Inc. etc., and it is expected that the business scale and profitability of Fosun Pharma in the fields like healthcare service, medical instruments and medical diagnostics will be further upgraded and enhanced.